华蟾素注射液对人肝癌HepG-2细胞增殖及凋亡的影响(英文)

被引:0
作者
Yu Sun1
机构
关键词
Cinobufacini injection; hepatocarcinoma; HepG-2; cells; apoptosis; TOPO I; TOPO II;
D O I
暂无
中图分类号
R285.5 [中药实验药理]; R735.7 [肝肿瘤];
学科分类号
100214 ; 1008 ;
摘要
Objective: The aim of our study was to investigate the effect of Cinobufacini injection on the proliferation and apoptosis of human hepatocarcinoma HepG-2 cells.Methods: Cells proliferation was assessed by MTT assay,cells morphologic was observed by the inverted microscopy,Annexin V/PI stain was used to detect the apoptosis and necrosis of the tumor cells.The expression of TOPO I mRNA and TOPO II mRNA were examined by RT-PCR.Results: Cinobufacini injection significantly inhibited HepG-2 cells proliferation in doseand time-dependent ways.After Cinobufacini injection intervention,HepG-2 cells showed typical morphological changes: cells changed from polygon into round,chromatin looseness and karyolysis were observed.The percentages of apoptosis were 88.49%,76.02%,61.73% corresponding to the 48 h interference of 0.42 μg/mL,0.21 μg/mL,0.105 μg/mL Cinobufacini injection,perspectively.RT-PCR assay showed that Cinobufacini injection down-regulated TOPO I and TOPO II expression at mRNA level.Conclusion: Cinobufacini can inhibit human hepatocarcinoma HepG-2 cells growth and induce tumor cells apoptosis,the mechanism of which might partly relate to the down-regulation of TOPO I mRNA and TOPO II mRNA induced by Cinobufacini injection.
引用
收藏
页码:27 / 30
页数:4
相关论文
共 9 条
[1]   华蟾素注射液对人肝癌HepG-2细胞DNA拓扑异构酶Ⅰ的影响 [J].
陈华 ;
孙宇 ;
崔晓楠 .
中国癌症杂志, 2010, 20 (03) :197-201
[2]   蟾酥及其活性成分抗肿瘤作用研究进展 [J].
刘俊珊 ;
张冬梅 ;
栗原博 ;
叶文才 .
国际药学研究杂志, 2009, 36 (02) :115-120
[3]   肝癌靶向药物治疗的研究进展 [J].
周立新 ;
郭剑民 .
肿瘤学杂志, 2009, (02) :156-161
[4]   华蟾素诱导人胃癌细胞株BGC-823凋亡实验研究 [J].
韩鸿彬 ;
陈嘉勇 ;
袁勇 ;
梁道明 ;
张毅 .
中国肿瘤, 2008, (03) :233-235
[5]   Caspase-3参与调控蟾酥诱导人肺腺癌(ASTC-a-1)细胞的凋亡 [J].
陈同生 ;
王小平 ;
孙磊 ;
王会营 ;
王龙祥 .
生物化学与生物物理进展, 2008, (01) :85-90
[6]   蟾蜍灵在诱导HL-60细胞凋亡过程中对Bcl-2和PKC的影响 [J].
田昕 ;
王萍萍 ;
刘云鹏 ;
侯科佐 ;
金波 ;
罗颖 ;
曲秀娟 .
中国实验血液学杂志, 2007, (01) :67-71
[7]  
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J] . Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Lancet Oncology . 2009 (1)
[8]   Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs [J].
Hashimoto, S ;
Jing, YK ;
Kawazoe, N ;
Masuda, Y ;
Nakajo, S ;
Yoshida, T ;
Kuroiwa, Y ;
Nakaya, K .
LEUKEMIA RESEARCH, 1997, 21 (09) :875-883
[9]   BUFALIN INDUCES APOPTOSIS AND INFLUENCES THE EXPRESSION OF APOPTOSIS-RELATED GENES IN HUMAN LEUKEMIA-CELLS [J].
MASUDA, Y ;
KAWAZOE, N ;
NAKAJO, S ;
YOSHIDA, T ;
KUROIWA, Y ;
NAKAYA, K .
LEUKEMIA RESEARCH, 1995, 19 (08) :549-556